Holen Sie sich die Stockscreener-App
11.01
3.00%
-0.34
Handel nachbörslich:
11.01
Schlusskurs vom Vortag:
$11.35
Offen:
$11.26
24-Stunden-Volumen:
302.09K
Relative Volume:
0.75
Marktkapitalisierung:
$464.62M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-3.00
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
+7.52%
1M Leistung:
+3.38%
6M Leistung:
-33.07%
1J Leistung:
-29.87%
1-Tages-Spanne:
$10.84
$11.40
1-Wochen-Bereich:
$10.21
$11.64
52-Wochen-Spanne:
$9.78
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
11.01 | 464.62M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian
UroGen Takes Center Stage: Double Feature at Elite Healthcare Investment Forums - StockTitan
JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
JELMYTO shows promise in long-term cancer treatment study By Investing.com - Investing.com Australia
JELMYTO shows promise in long-term cancer treatment study - Investing.com
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC - MarketBeat
UroGen Pharma Reveals Promising Developments in Latest 8-K Filing - Defense World
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral Capital - MarketBeat
UroGen's UGN-102 shows high response in bladder cancer study By Investing.com - Investing.com South Africa
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - BioSpace
UroGen's UGN-102 shows high response in bladder cancer study - Investing.com
Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - Simply Wall St
UroGen Pharma Highlights RTGel® Platform and Growth Plans - TipRanks
Jane Street Group LLC Sells 8,198 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
How To Trade (URGN) - Stock Traders Daily
Geode Capital Management LLC Purchases 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Brokerages - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by State Street Corp - Defense World
Fmr LLC Buys 19,670 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN stock touches 52-week low at $10.6 amid market challenges - Investing.com Canada
URGN stock touches 52-week low at $10.6 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70 - MarketBeat
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
(URGN) Investment Report - Stock Traders Daily
UroGen Pharma Grants 112,800 RSUs to Expand Commercial Team for Jelmyto Rollout - StockTitan
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Urogen Pharma Ltd. Announces Long-Term Follow-Up Study to the Olympus Trial Presented At SUO 2024 - Marketscreener.com
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
URGN (UroGen Pharma) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma Ltd. (NASDAQ:URGN) Holdings Raised by RTW Investments LP - MarketBeat
UroGen's Bladder Cancer Drug Shows Breakthrough 82% Response Rate in Phase 3 Trial - StockTitan
Parkman Healthcare Partners LLC Has $4.41 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade - Yahoo Finance
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - BioSpace
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):